Martin-Iguacel R, Llibre J M, Friis-Moller N
Infectious Diseases Department, Odense University Hospital, Søndre Boulevard 29, 5000, Odense C, Denmark.
HIV Unit and "Lluita contra la SIDA" Foundation, Hospital Universitari Germans Trias i Pujol. Badalona, Barcelona, Spain.
Curr HIV/AIDS Rep. 2015 Dec;12(4):375-87. doi: 10.1007/s11904-015-0284-6.
With more effective and widespread antiretroviral treatment, the overall incidence of AIDS- or HIV-related death has decreased dramatically. Consequently, as patients are aging, cardiovascular disease (CVD) has emerged as an important cause of morbidity and mortality in the HIV population. The incidence of CVD overall in HIV is relatively low, but it is approximately 1.5-2-fold higher than that seen in age-matched HIV-uninfected individuals. Multiple factors are believed to explain this excess in risk such as overrepresentation of traditional cardiovascular risk factors (particularly smoking), toxicities associated with cumulative exposure to some antiretroviral agents, together with persistent chronic inflammation, and immune activation associated with HIV infection. Tools are available to calculate an individual's predicted risk of CVD and should be incorporated in the regular follow-up of HIV-infected patients. Targeted interventions to reduce this risk must be recommended, including life-style changes and medical interventions that might include changes in antiretroviral therapy.
随着更有效且广泛的抗逆转录病毒治疗,艾滋病或与HIV相关的死亡总体发生率已大幅下降。因此,随着患者年龄增长,心血管疾病(CVD)已成为HIV人群发病和死亡的重要原因。HIV人群中CVD的总体发生率相对较低,但比年龄匹配的未感染HIV个体高出约1.5至2倍。多种因素被认为可解释这种额外的风险,如传统心血管危险因素(尤其是吸烟)的过度存在、与长期接触某些抗逆转录病毒药物相关的毒性、持续的慢性炎症以及与HIV感染相关的免疫激活。有工具可用于计算个体患CVD的预测风险,并应纳入HIV感染患者的定期随访中。必须推荐针对性干预措施以降低这种风险包括生活方式改变和可能包括抗逆转录病毒治疗调整的医学干预措施。